21 completed, 3 active not recruiting, 3 terminated, 3 unknown. 25 Phase 2, 13 Phase 1, 2 Phase 3, 1 Early Phase 1.
Follow Ixazomib Citrate: new trials by email Literature Review of Ixazomib Citrate trials Research Report on Ixazomib Citrate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Ixazomib for Kaposi Sarcoma Ixazomib Citrate, Quality-of-Life Assessment, Questionnaire Administration - Kaposi Sarcoma, Skin | Phase 2 | Recruiting | AIDS Malignancy Consortium | 41 | 2023-11-07 | 2026-02-27 |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography - Recurrent AL Amyloidosis, Refractory AL Amyloidosis | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-08-03 | 2026-07-31 |
| Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Multiple Myeloma | Phase 3 | Completed | National Cancer Institute (NCI) | 1 | 2022-02-16 | 2025-05-23 |
| Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment Ixazomib Citrate, Pevonedistat - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Completed | National Cancer Institute (NCI) | 8 | 2020-02-10 | 2025-06-19 |
| A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Ixazomib, Thalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Withdrawn | Takeda | 2019-09-30 | 2020-01-14 | |
| Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Ixazomib, Ixazomib Citrate, Rituximab - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2019-08-28 | 2025-04-20 |
| Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma Dexamethasone, Ixazomib, Ixazomib Citrate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2019-06-21 | 2019-03-26 | |
| Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy Abatacept, Dexamethasone, Ixazomib Citrate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | Roswell Park Cancer Institute | 15 | 2018-09-11 | 2025-03-04 |
| Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Doxorubicin, Doxorubicin Hydrochloride, Gemcitabine - Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 30 | 2018-08-17 | 2026-08-11 |
| Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia Ibrutinib, Ixazomib Citrate, Laboratory Biomarker Analysis - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 2 | Terminated | Mayo Clinic | 21 | 2018-08-14 | 2026-05-05 |
| Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis - Recurrent Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 13 | 2018-06-19 | 2024-01-09 |
| Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis - Recurrent Plasma Cell Myeloma, T(11;14) | Phase 1 | Completed | Mayo Clinic | 8 | 2018-05-02 | 2024-11-04 |
| Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 8 | 2017-07-24 | 2023-09-21 |
| Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma Daratumumab, Dexamethasone, Ixazomib Citrate - Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 80 | 2017-04-20 | 2025-06-04 |
| Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome Dexamethasone, Ixazomib Citrate, Lenalidomide - Plasmacytoma, POEMS Syndrome | Early Phase 1 | Completed | Mayo Clinic | 21 | 2016-10-31 | 2025-02-12 |
| Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement Dexamethasone, Ixazomib, Lenalidomide - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Completed | Emory University | 70 | 2016-09-01 | 2025-06-26 |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Ixazomib Citrate, Laboratory Biomarker Analysis, Rituximab - Chronic Lymphocytic Leukemia, Follicular Lymphoma | Phase 2 | Active not recruiting | University of Washington | 33 | 2016-05-19 | 2026-07-01 |
| Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission Ixazomib, Rituximab - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Emory University | 12 | 2016-03-01 | 2023-05-09 |
| Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma Ixazomib Citrate, Laboratory Biomarker Analysis, Lenalidomide - Plasma Cell Myeloma, Transplant-Related Carcinoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 30 | 2015-12-30 | 2026-09-25 |
| Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Dexamethasone, Idasanutlin, Ixazomib Citrate - Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 33 | 2015-12-30 | 2024-09-19 |
Showing 20 of 33. Sign in to see all of them.
Multiple Myeloma (21) · Lymphoma, Mantle-Cell (3) · Leukemia, Plasma Cell (2) · Neoplasms, Plasma Cell (2) · Plasmacytoma (2) · Waldenstrom Macroglobulinemia (2) · Amyloidosis (1) · Bronchiolitis Obliterans Syndrome (1) · Burkitt Lymphoma (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Chromosome 17 deletion (1) · Immunoglobulin Light-chain Amyloidosis (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1)
Mayo Clinic (10) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · Emory University (2) · Fred Hutchinson Cancer Center (2) · Takeda (2) · AIDS Malignancy Consortium (1) · City of Hope Medical Center (1) · Joseph Tuscano (1) · Millennium Pharmaceuticals, Inc. (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · University of Chicago (1) · University of Washington (1)
United States (31) · Brazil (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Colombia (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1)
Shaji Kumar, M.D. (4) · Ajay K. Gopal (1) · Amrita Krishnan (1) · Andrzej Jakubowiak (1) · Angela Dispenzieri, M.D. (1) · Arlene O Siefker-Radtke (1) · Asher A. Chanan-Khan, M.D. (1) · Barbara Pro, MD (1) · Erin Reid, MD (1) · Hun J Lee (1) · Jens Hillengass, MD, PhD (1) · Jonathon Cohen, MD, MS (1) · Joseph Tuscano (1) · Krina Patel (1) · Leon Bernal-Mizrachi, MD (1)
PMID 24904120, PMID 27702799, PMID 28803351, PMID 30545780, PMID 31880006, PMID 32613281, PMID 35737873, PMID 36130300, PMID 36180329, PMID 36385536, PMID 38237077, PMID 40226119, PMID 40948663
P30CA138292 (2), P30CA014599 (1), P30CA015083 (1), P30CA015704 (1), P30CA060553 (1), U10CA180820 (1), UM1CA121947 (1), UM1CA186644 (1), UM1CA186691 (1), UM1CA186717 (1)